APA (7th ed.) Citation

H, R., L, T., T, P., K, S., J, W., J, B., . . . D, T. (2026). Oxaliplatin resistance in pancreatic ductal adenocarcinoma is non‑significantly mediated by diminished drug uptake but is highly linked to a poor apoptotic response to the cytotoxic threat. Oncology reports, 55(1), . https://doi.org/10.3892/or.2025.9027

Chicago Style (17th ed.) Citation

H, Röttgen, Theurer L, Peccerella T, Sandu K, Weiss J, Burhenne J, Neoptolemos JP, Köberle B, and Theile D. "Oxaliplatin Resistance in Pancreatic Ductal Adenocarcinoma Is Non‑significantly Mediated by Diminished Drug Uptake but Is Highly Linked to a Poor Apoptotic Response to the Cytotoxic Threat." Oncology Reports 55, no. 1 (2026). https://doi.org/10.3892/or.2025.9027.

MLA (9th ed.) Citation

H, Röttgen, et al. "Oxaliplatin Resistance in Pancreatic Ductal Adenocarcinoma Is Non‑significantly Mediated by Diminished Drug Uptake but Is Highly Linked to a Poor Apoptotic Response to the Cytotoxic Threat." Oncology Reports, vol. 55, no. 1, 2026, https://doi.org/10.3892/or.2025.9027.